VIEWS: 1 PAGES: 2 CATEGORY: Medicine POSTED ON: 6/5/2010
The business and medical analysis we can already perform would have been impossible or prohibitively expensive just a few years ago. Availability of data from regulatory agencies, WHO and healthcare providers has already enabled detailed market analyses, more effective safety and clinical reviews.
NOSTRAPHARMUS DATA: THE ROOT Of ALL ... GOOD? nostrapharmus suggests that the drug community will share a single data set I across research, development, marketing, safety and more. ncreasingly, the ability to store, manipulate, and • Understanding market size query vast quantities of data is enabling us to • Spotting demographic/health trends perform key business and medical analysis, without • Recruitment for clinical trials the need for much of the legwork of old. Not only • Early detection of safety issues is it easier than ever to structure and query data, • Vastly improved capacity for observational trials but also the advent of data mining has also opened up new • Linkage of molecular form to clinical function. opportunities to learn from a wider range of data and from older, unstructured data. The challenge The computer age has prepared us well for this new era. Numerous challenges lie ahead, and the competitive threat Data have been captured in digitized form for a few decades. introduced through the sharing of much of the data will be a As time has progressed, the data set of every business in major concern for all of the commercial contributors across the sector has grown. This data, newly generated data, and the pharmaceutical and healthcare sectors. However, in much everyone else’s data, now present the chance to unearth new the same way as clinical trial data are shared across industry knowledge, hidden within the depths of the hard drive. systems, patient treatment and outcomes information could be shared without compromising confidentiality or breaching The company opportunity data protection laws. The imperative is already in place, to leverage the data you have from the development and subsequent commercial use The Way Forward of your products, to anticipate patient safety issues and to Healthcare and clinical data standards will need to recognize when patient safety issues are manifesting. This be developed and agreed, data exchange agreements is clearly good for patients, but it is also unquestionably established and repositories set up. The pharmaceutical good for business — demonstrating a responsible attitude world is already overloaded with complex safety data to your ultimate customers, while protecting, and even exchange agreements. These are often out of date compared
Pages to are hidden for
"DATA: THE ROOT OF ALL . . . GOOD?"Please download to view full document